APOC3 and coronary artery disorder: The variants were then tested for association with CHD in 110,097 individuals from 15 different studies [25]: it has been descripted that rare LOF APOC3 mutations decrease both TG and ApoC-III plasma levels and in the same time reduce the CHD risk, since mutation carriers exhibited a 40% decrease in CHD compared to non-carriers.